Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

Publisher： Karger

E-ISSN： 1662-6575|10|2|548-552

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.10, Iss.2, 2017-06, pp. : 548-552

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab

By  

Case Reports in Oncology, Vol. 2, Iss. 2, 2009-07 ,pp. : 111-115

Karger

Access to resources Recommend Favorite

Patient Expectations of Benefit from Phase I Clinical Trials: Linguistic Considerations in Diagnosing a Therapeutic Misconception

By Weinfurt K.P.  

Theoretical Medicine, Vol. 24, Iss. 4, 2003-01 ,pp. : 329-344

Springer Publishing Company

Access to resources Recommend Favorite

Tumour‐to‐tumour metastasis from papillary thyroid carcinoma with BRAF mutation to lung adenocarcinoma with EGFR mutation: the utility of mutation‐specific antibodies

By  

HISTOPATHOLOGY, Vol. 67, Iss. 2, 2015-08 ,pp. : 262-266

John Wiley & Sons Inc

Access to resources Recommend Favorite

Primary Adenocarcinoma Arising from a Paraurethral Cyst in a Female Patient

By  

Urologia Internationalis, Vol. 69, Iss. 3, 2002-10 ,pp. : 244-246

Karger

Access to resources Recommend Favorite

Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 298-304

Karger

Access to resources Recommend Favorite